These results are in concordance with EPIC analysis: We did not find EGFR amplification in WHO Grade 1 and 2 gliomas but found mean EGFR relative probe intensities of 0.3 in CNS WHO Grade 4 gliomas (Figure 2f). This evidence concerns the gene EGFR and central nervous system cancer.